CYP2D6 inhibition in patients treated with sertraline
- PMID:10950472
- DOI: 10.1097/00004714-199704000-00007
CYP2D6 inhibition in patients treated with sertraline
Abstract
Sertraline, a selective serotonin reuptake inhibitor used to treat depression, inhibits CYP2D6 in vitro (Ki = 1.2 microM) less potently than fluoxetine (Ki = 0.15 microM). To determine the extent and time course of CYP2D6 inhibition in patients, six males (mean age: 40 years, range: 29-64 years), who were starting treatment for depression with sertraline, were phenotyped on five occasions (once before treatment and approximately 3, 7, 14, and 21 days later). Phenotype status was determined using oral dextromethorphan (30 mg) by calculating the urinary ratio of O-demethylated metabolites to parent drug (i.e., log ODMR). CYP2D6 genotype was determined by leukocyte DNA analysis using polymerase chain reaction amplification. Compliance was confirmed by sertraline plasma levels. Daily sertraline dosages ranged from 50 to 150 mg. Genotype results indicated all subjects were extensive metabolizers (four homozygous wild type [wt], two heterozygous wt/B mutation). Phenotype results showed that CYP2D6 inhibition in patients treated with sertraline appeared to be related to baseline CYP2D6 activity and sertraline dosage. Some patients with high CYP2D6 activity can demonstrate inhibition with sertraline dosages as low as 50 mg.
Similar articles
- The extent and determinants of changes in CYP2D6 and CYP1A2 activities with therapeutic doses of sertraline.Ozdemir V, Naranjo CA, Herrmann N, Shulman RW, Sellers EM, Reed K, Kalow W.Ozdemir V, et al.J Clin Psychopharmacol. 1998 Feb;18(1):55-61. doi: 10.1097/00004714-199802000-00009.J Clin Psychopharmacol. 1998.PMID:9472843
- CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations.Alfaro CL, Lam YW, Simpson J, Ereshefsky L.Alfaro CL, et al.J Clin Pharmacol. 2000 Jan;40(1):58-66. doi: 10.1177/00912700022008702.J Clin Pharmacol. 2000.PMID:10631623Clinical Trial.
- CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6.Lam YW, Gaedigk A, Ereshefsky L, Alfaro CL, Simpson J.Lam YW, et al.Pharmacotherapy. 2002 Aug;22(8):1001-6. doi: 10.1592/phco.22.12.1001.33603.Pharmacotherapy. 2002.PMID:12173784Clinical Trial.
- Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.Ereshefsky L, Riesenman C, Lam YW.Ereshefsky L, et al.Clin Pharmacokinet. 1995;29 Suppl 1:10-8; discussion 18-9. doi: 10.2165/00003088-199500291-00004.Clin Pharmacokinet. 1995.PMID:8846618Review.
- Spotlight on sertraline in the management of major depressive disorder in elderly patients.Muijsers RB, Plosker GL, Noble S.Muijsers RB, et al.CNS Drugs. 2002;16(11):789-94. doi: 10.2165/00023210-200216110-00011.CNS Drugs. 2002.PMID:12383038Review.
Cited by
- Drug-Drug Interactions between COVID-19 and Tuberculosis Medications: A Comprehensive Review of CYP450 and Transporter-Mediated Effects.Jony MR, Ahn S.Jony MR, et al.Pharmaceuticals (Basel). 2024 Aug 6;17(8):1035. doi: 10.3390/ph17081035.Pharmaceuticals (Basel). 2024.PMID:39204140Free PMC article.Review.
- Clinical pharmacokinetics of trospium chloride.Doroshyenko O, Jetter A, Odenthal KP, Fuhr U.Doroshyenko O, et al.Clin Pharmacokinet. 2005;44(7):701-20. doi: 10.2165/00003088-200544070-00003.Clin Pharmacokinet. 2005.PMID:15966754Review.
- The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders.MacQueen G, Born L, Steiner M.MacQueen G, et al.CNS Drug Rev. 2001 Spring;7(1):1-24. doi: 10.1111/j.1527-3458.2001.tb00188.x.CNS Drug Rev. 2001.PMID:11420570Free PMC article.Review.
- Antidepressants, metoprolol and the risk of bradycardia.Kurdyak PA, Manno M, Gomes T, Mamdani MM, Juurlink DN.Kurdyak PA, et al.Ther Adv Psychopharmacol. 2012 Apr;2(2):43-9. doi: 10.1177/2045125311433580.Ther Adv Psychopharmacol. 2012.PMID:23983956Free PMC article.
- Serotonin Syndrome in a Sertraline-Treated Man Taking NyQuil Containing Dextromethorphan for Cold.Sethi R, Kablinger AS, Kavuru B.Sethi R, et al.Prim Care Companion CNS Disord. 2012;14(6):PCC.12l01388. doi: 10.4088/PCC.12l01388.Prim Care Companion CNS Disord. 2012.PMID:23585992Free PMC article.No abstract available.
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources